Compugen vs Recursion Pharmaceuticals
CGEN and RXRX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CGEN and RXRX compare
Compugen grew revenue faster over the last twelve months (161% versus 56.2% for Recursion Pharmaceuticals).
Compugen keeps more of each dollar of sales as profit, with a net margin of 48.6% compared with −697% at Recursion Pharmaceuticals.
Compugen scores higher on the StockData Score (12 against 8 for Recursion Pharmaceuticals), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CGEN | RXRX |
|---|---|---|
| Size and price | ||
| Market cap | – | $1.7B |
| Share price | $2.10 | $3.19 |
| Change, 1 year | 25.0% | −31.5% |
| Change, 5 years | −55.4% | −83.9% |
| Beta (5Y) | 1.61 | 2.65 |
| Employees | 2 | 50 |
| StockData Score | ||
| Total score | 12 (better) | 8 |
| Valuation score | 0 | 1 (better) |
| Growth score | 3 | 3 |
| Performance score | 4 (better) | 2 |
| Health score | 5 (better) | 2 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | – | 25.0× |
| P/B | – | 1.9× |
| FCF yield | – | −18.3% |
| Fair value | – | $3.14 |
| Margin of safety | – | −1.5% |
| Growth | ||
| Revenue growth (TTM) | 161% (better) | 56.2% |
| Revenue growth, 5Y average | 105% (better) | 79.9% |
| Profitability | ||
| Gross margin | 87.3% (better) | 29.2% |
| Operating margin | 43.1% (better) | −725% |
| Net margin | 48.6% (better) | −697% |
| FCF margin | 43.1% (better) | −458% |
| Return on equity | 50.9% (better) | −48.7% |
| Return on invested capital | 117% (better) | −102% |
| Financial health | ||
| Debt / equity | 0.00 | 0.01 (better) |
| Interest coverage | – | −541.6× |
| Current ratio | 5.72 (better) | 5.01 |
| Altman Z-score | – | −0.36 |
| Piotroski F-score | 7 (better) | 3 |
| Dividends and buybacks | ||
| Buyback yield | – | −12.8% |
| Shareholder yield | – | −12.8% |
| Ownership | ||
| Held by institutions | – | 67.6% |
| Held by insiders | 0.43% | 5.6% |
| Insider net buying, 12 months | −$126K (better) | −$7.4M |
| Short interest, % of float | 2.7% | 28.2% |
Go deeper
- CGEN stock overview
- CGEN income statement
- CGEN valuation and score
- RXRX stock overview
- RXRX income statement
- RXRX valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.